DEBASISH TRIPATHY to Disease Progression
This is a "connection" page, showing publications DEBASISH TRIPATHY has written about Disease Progression.
Connection Strength
0.130
-
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15; 22(6):1063-70.
Score: 0.026
-
Systemic therapy for advanced breast cancer. Breast J. 2004 Jan-Feb; 10 Suppl 1:S26-7.
Score: 0.026
-
Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist. 2004; 9(4):361-77.
Score: 0.026
-
Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. J Bone Miner Res. 2016 08; 31(8):1569-76.
Score: 0.015
-
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011 Jul 15; 17(14):4834-43.
Score: 0.011
-
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9393-8.
Score: 0.007
-
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
Score: 0.006
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.005
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999 Sep; 17(9):2639-48.
Score: 0.005
-
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998 Aug; 16(8):2659-71.
Score: 0.004